Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q2 FY25 results · Jul–Sep 2024
Supriya Lifescience reported revenue from operations of ₹166.10 crore (up 18.6% from Q2 FY24) and net profit of ₹46.15 crore (up 93.2% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a standalone basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 166.10 | 140.09 | +18.6% | 160.63 | +3.4% |
| Other income | 2.52 | 2.47 | +2.1% | 2.22 | +13.2% |
| Total income | 168.62 | 142.56 | +18.3% | 162.85 | +3.5% |
| Profit before tax | 62.06 | 29.78 | +108.4% | 59.77 | +3.8% |
| Net profit for the period | 46.15 | 23.88 | +93.2% | 44.64 | +3.4% |
| EPS, basic (₹) | 5.71 | 2.97 | +92.3% | 5.54 | +3.1% |
| Net margin (%) | 27.8 | 17.0 | 27.8 |
Standalone
- Filed with BSE
- 12 Nov 2024, 12:12 IST
- Board meeting
- 28 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE